http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2332569-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ea4440eb72b01216fb4c86a0b66b11c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
filingDate 2005-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da876ee764e7d2c815ec0a378158c1c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ddf7e9216f37c1f0ce93d0586c779c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4dc53e6fd67f20f0e5f941968f6ba40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c9ae4dc8cb18ec2e8a8491a8fbf8a18
publicationDate 2011-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2332569-A3
titleOfInvention Compositions and methods for treating neurological disorders
abstract Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic diseases, and/or neurodegenerative autoimmune disorders are described. Methods of using said compositions also are described. In particular, methods to treat a neurodegenerative disorder such as Alzheimer's disease and a neurodegenerative autoimmune disorder such as Multiple Sclerosis are contemplated utilizing proteosomes and/or Glatiramer Acetate, wherein the GA is in a submicron emulsion or a nanoemulsion.
priorityDate 2004-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02072012-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0152878-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3081884
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448746680

Total number of triples: 35.